ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

Also written as “Symbicort Turbuhaler”, “Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)” and “Budesonide/formoterol (Symbicort® Turbuhaler®)”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageBudesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 17, 200710 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca80 open or runningphase 4since Dec 17, 2007Oct 6, 2006none ahead
Chenpon Pharmaceuticalits history only10 open or runningphase 1since Aug 31, 2026Aug 31, 2026none ahead
Orion Corporation, Orion Pharmaits history only10 open or runningphase 1since Mar 24, 2009Mar 24, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2006First study: phase 3 study in AsthmaFirst studyNCT00385593 · 654 enrolled · Spain
  2. Sep 27, 2007Phase 3 study in AsthmaNCT00536731 · 742 enrolled · Bulgaria, Czech Republic, Hungary and more
  3. Dec 17, 2007Phase 4 study in AsthmaNCT00576316 · 201 enrolled · Malaysia
  4. Feb 4, 20092 phase 3 studies in AsthmaNCT00839800, NCT00837967
  5. Feb 11, 20102 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT01070784, NCT01069289
  6. Jun 27, 2011Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT01397890 · 793 enrolled · China, Hong Kong, Indonesia and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01397890Pulmonary Disease, Chronic Obstructive · China, Hong Kong, Indonesia and more4CompletedJun 2013793
NCT01070784Pulmonary Disease, Chronic Obstructive · Japan3CompletedOct 2011328
NCT01069289Pulmonary Disease, Chronic Obstructive · India, Japan, Korea, Republic of and more3CompletedMar 20111,293
NCT00837967Asthma · Japan3CompletedJul 200925
NCT00839800Asthma · Argentina, Brazil, China and more3CompletedFeb 20112,091
NCT00576316Asthma · Malaysia4Completed201
NCT00536731Asthma · Bulgaria, Czech Republic, Hungary and more3CompletedApr 2008742
NCT00385593Asthma · Spain3Terminated654

How it is read

Names in the registry

  • “Symbicort Turbuhaler”, 3 entries
  • “Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)”, 1 entry
  • “Budesonide/formoterol (Symbicort® Turbuhaler®)”, 1 entry
  • “Symbicort Turbuhaler (Budesonide/formoterol)”, 1 entry
  • “Budesonide/formoterol (Symbicort Turbuhaler)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.